ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04042740 (Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of direct-acting antiviral regimens for acute HCV infection: a systematic review and meta-analysis.Virology journal · 2026Pooled it
- Modeling predicts shortening of DAA treatment duration to 5 weeks in individuals with recent or chronic infection with HCV RNA negativity at day 7 on treatment.The Journal of infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundShorter treatment courses for early hepatitis C virus (HCV) infection could simplify treatment approaches, particularly in key populations.
methodsPURGE-C (A5380) was a single-arm, multicenter trial evaluating the treatment of early HCV (primary or reinfection) with 4 weeks of glecaprevir/pibrentasvir (G/P). Early HCV was defined as new detectable HCV RNA or alanine aminotransferase (ALT) elevation within 24 weeks of study entry. The primary endpoint was sustained virologic response (SVR) 12 weeks after prescribed treatment completion (SVR12). Re-treatment outcomes were also collected.
resultsForty-five participants (98% male, 51% White, 31% Hispanic, median age 36 years, 51% with human immunodeficiency virus [HIV], 27% self-reported injecting drugs) were enrolled from the United States and Brazil between November 2019 and January 2023. Median time from HCV diagnosis to entry was 31 days (Q1-Q3: 15-49). Median baseline HCV RNA was 5.3 log10 IU/mL (Q1-Q3: 3.3-6.0) and ALT 146 U/L (min-max: 22-3866). Overall, 38 of 45 (84%) participants (90% confidence interval [CI]: 74%-91%) achieved SVR12. All 4 participants who were retreated and had outcome data achieved SVR12.
conclusionsIn this population with elevated risk of onward HCV transmission, 84% were cured with 4 weeks of G/P. Failing this short-course treatment did not compromise retreatment. This study suggests that people with early HCV infection can achieve moderately high cure rates with abbreviated courses of direct-acting antivirals (DAA). Simplified approaches to treatment are critical for HCV elimination and are particularly relevant for populations difficult to retain in care. CLINICAL
trial registrationNCT04042740.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.